Lipopeptide – an operational unit of Pergamum
Lipopeptide develops novel treatments for venous leg ulcers and diabetic foot ulcers based on the therapeutic peptide LL-37. Up to 5% of people aged 65 years or above will develop a venous leg ulcer (VLU) during their lifetime.
LL-37 is a multifunctional antimicrobial peptide with confirmed wound healing properties both in vitro and in vivo. The peptide is formulated for easy wound application in connection with regular wound care. This product has the potential to be a beak-though in the treatment of a painful, disabling and growing disease where there are no effective treatments available.
Lipopeptide is based in Stockholm, Sweden and was formed by leading scientists in dermatology at Karolinska Institutet. In 2011 the company merged with PharmaSurgics and Dermagen to form Pergamum.